Discover
BNTC
Benitec Biopharma Inc.
12.69
2 x 9.56
2 x 16.30
bid
ask
-
0.69
5.16%
2 @ 04:00 PM
12.69 +0.00 (0.00%)
| Ytd | -5.79% | |
| 1y | 4.79% |
12.66
day range
13.49
9.85
52 week range
16.76
| Open | 13.26 | Prev Close | 13.38 | Low | 12.66 | High | 13.49 | Mkt Cap | 435.96M |
| Vol | 114.52K | Avg Vol | 115.41K | EPS | -0.93 | P/E | N/A | Forward P/E | -1.23 |
| Beta | 0.88 | Short Ratio | 1.35 | Inst. Own | 82.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 11.81 | 200-d Avg | 12.52 | 1yr Est | 25.43 |
| Income Statement | |||
| Operating Expenses | 13.58M | ||
| Research and Development Expense | 6.30M | ||
| Selling, General and Administrative Expense | 7.28M | ||
| Operating Income | -13.58M | ||
| Net Income | -11.93M | ||
| Net Income Common Stock | -11.93M | ||
| Net Income Common Stock (USD) | -11.93M | ||
| Consolidated Income | -11.93M | ||
| Earnings per Basic Share | 0.00 | ||
| Earnings per Basic Share (USD) | 0.00 | ||
| Earnings per Diluted Share | 0.00 | ||
| Earning Before Interest & Taxes (EBIT) | -11.93M | ||
| Earning Before Interest & Taxes (USD) | -11.93M | ||
| Weighted Average Shares | 49.39M | ||
| Weighted Average Shares Diluted | 49.39M | ||
| Balance Sheet | |||
| Cash and Equivalents | 184.93M | ||
| Cash and Equivalents (USD) | 184.93M | ||
| Trade and Non-Trade Receivables | 3.00K | ||
| Current Assets | 186.02M | ||
| Property, Plant & Equipment Net | 916.00K | ||
| Total Assets | 187.00M | ||
| Debt Current | 482.00K | ||
| Total Debt | 876.00K | ||
| Current Liabilities | 3.27M | ||
| Debt Non-Current | 394.00K | ||
| Total Liabilities | 3.67M | ||
| Accumulated Retained Earnings (Deficit) | -260.91M | ||
| Accumulated Other Comprehensive Income | -952.00K | ||
| Shareholders Equity | 183.33M | ||
| Shareholders Equity (USD) | 183.33M | ||
| Assets Non-Current | 983.00K | ||
| Total Debt (USD) | 876.00K | ||
| Liabilities Non-Current | 394.00K | ||
| Trade and Non-Trade Payables | 2.25M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 119.00K | ||
| Net Cash Flow from Financing | 506.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -4.03M | ||
| Capital Expenditure | -15.00K | ||
| Issuance (Purchase) of Equity Shares | 507.00K | ||
| Net Cash Flow from Investing | -15.00K | ||
| Net Cash Flow from Operations | -4.45M | ||
| Effect of Exchange Rate Changes on Cash | -67.00K | ||
| Share Based Compensation | 7.59M | ||